Pleural effusion as the first manifestation of pulmonary toxoplasmosis in a bone marrow transplant recipient.
D000818:Animals; D000977:Antiparasitic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006644:Histiocytes / Q000469:parasitology / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007951:Leukemia, Myeloid / Q000628:therapy; D008168:Lung / Q000469:parasitology / Q000473:pathology / Q000503:physiopathology; D008174:Lung Diseases, Parasitic / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D008875:Middle Aged; D009894:Opportunistic Infections / Q000276:immunology / Q000469:parasitology / Q000473:pathology; D010996:Pleural Effusion / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D012128:Respiratory Distress Syndrome / Q000276:immunology / Q000469:parasitology / Q000473:pathology; D014122:Toxoplasma / Q000166:cytology / Q000276:immunology / Q000472:pathogenicity; D014123:Toxoplasmosis / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D017211:Treatment Failure
D000977:Antiparasitic Agents